Top-News
Donnerstag,
11.05.2017 14:05
von
PR Newswire
| Aufrufe: 175
Guardant Health Partners with SoftBank to Accelerate Efforts in Early Cancer Detection
Ärzte in einem Operationssaal (Symbolbild).
© FangXiaNuo / E+ / Getty Images
http://www.gettyimages.de/
PR Newswire
REDWOOD CITY, Calif., May 11, 2017
REDWOOD CITY, Calif., May 11, 2017 /PRNewswire/ -- Guardant Health, the world leader in comprehensive liquid biopsies, announced an ambitious goal to sequence the tumor DNA of more than 1 million cancer patients within five years. Guardant Health expects the data from the Guardant 1 Million effort to fuel fundamental advancements across the continuum of cancer care, and accelerate the development of blood-based tests for early cancer detection.
"We believe that conquering cancer is at its core a big-data problem, and researchers have been data starved," said Helmy Eltoukhy, Guardant Health Co-Founder and CEO. "Our launch of the world's first commercial comprehensive liquid biopsy sparked a boom in cancer data acquisition. Every physician who orders one of our tests and every patient whose tumor DNA we sequence add to this larger mission by improving our understanding of this complex disease. With this ambitious five-year effort, we intend to accelerate this progress and provide a much-needed infusion of data into the field."
Guardant Health has secured $360 million in new funding that will help it reach its goal of sequencing 1 million cancer patients faster than any previous initiative or clinical trial. A SoftBank Group subsidiary is the lead investor, with participation from certain funds and accounts managed by T. Rowe Price, Associates, Inc., Temasek, and others including existing investors Sequoia Capital, Khosla Ventures, Lightspeed Venture Partners, OrbiMed, and 8VC. With this funding, Guardant Heath has raised more than $500 million.
Cancer is the second leading cause of death globally. By 2030, researchers expect 21 million new cases per year. Early detection of cancer can dramatically improve patient outcomes by catching the disease before it has spread, but many current cancer screening methods risk false positives and overdiagnosis.
Guardant Health's vision has always been to develop products for early cancer detection. The company first created Guardant360, a test that helps patients with advanced cancer, to address an urgent unmet medical need and also because the technical expertise and data acquired by testing more developed tumors are critical for work with early detection. Oncologists have ordered Guardant360 more than 35,000 times, making it the most widely used comprehensive liquid biopsy.
Guardant Health and SoftBank also announced the formation of a new joint venture to expand commercialization of Guardant Health's industry-leading liquid biopsy technology in Asia, the Middle East, and Africa, regions where more than 7.8 million new cases of cancer are diagnosed each year.
Masayoshi Son, SoftBank Group Chairman and CEO, said, "Guardant Health is applying the breakthrough technologies of machine learning and genomics to cancer – one of the world's biggest challenges. Guardant's approach is built on smart science and a smart business model, in which its capabilities grow each time a doctor uses its services. Our investment will enable Guardant, already the clear leader in an exciting field, to become the Rosetta Stone for cancer, across all stages."
ARIVA.DE Börsen-Geflüster
Werbung
Weiter aufwärts?
| Kurzfristig positionieren in Softbank Group Corp. ADR | ||
|
ME923U
| Ask: 0,14 | Hebel: 4,18 |
| mit moderatem Hebel |
Zum Produkt
| |
Morgan Stanley
Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie hier: ME923U,. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Kurse
 |
This financing will support work to expand Project LUNAR, Guardant Health's early cancer detection efforts announced in 2016. The initial LUNAR products will look for evidence of residual disease in patients who have undergone surgery, radiation, or other treatments intended to cure them of cancer. Then, Guardant Health expects to introduce tests to identify early signs of cancer in high-risk patients who have not yet been diagnosed.
"We believe our rapid, iterative approach will generate the data necessary to develop non-invasive tests that are both sensitive enough to detect cancer early in high-risk populations, and specific enough to avoid inflicting unnecessary anxiety and harm through overdiagnosis," said AmirAli Talasaz, Guardant Health Co-Founder and President.
BACKGROUND: GUARDANT HEALTH PRODUCTS AND CANCER
About Guardant360 and Comprehensive Liquid Biopsies
Liquid Biopsies are an increasingly important tool used by oncologists to help match patients with advanced cancer to an appropriate therapy. For some advanced cancer patients, targeted drugs can be more effective and less toxic than standard chemotherapy. But these targeted drugs only work when the patient's tumor DNA contains specific genomic alterations. In the past, the only way to learn if a tumor harbored such a mutation was to sequence tissue that was removed through a biopsy. These procedures can be expensive, risky, and painful.
A comprehensive liquid biopsy examines the tiny fragments of DNA, known as circulating tumor DNA or ctDNA, that are released into the blood stream by dying tumor cells, and provides a genomic profile without requiring patients to undergo an invasive tissue biopsy
Guardant360 is the most widely ordered comprehensive liquid biopsy. It was introduced in 2014 and has since been ordered by more than 3,000 oncologists for more than 35,000 patient samples. The Guardant360 assay includes 73 genes associated with cancer, and can detect single nucleotide variants, insertion and deletion events, copy number amplifications, and fusions.
About Project LUNAR
Project LUNAR is Guardant Health's effort to apply the technology behind Guardant360 to the more challenging problems of detecting residual disease in cancer survivors and detecting early stage disease in people who are at high risk of developing cancer. Guardant Health began collecting Project LUNAR samples in 2016. The first products developed under Project LUNAR will address detecting residual disease in patients who have already had surgery or other treatments such as radiation or chemotherapy intended to cure them of cancer. The second phase of Project LUNAR will focus on tests to screen high-risk populations for early signs of cancer.
About Guardant Health
Guardant Health is focused on conquering cancer by using its breakthrough blood-based assays, vast data sets, and advanced analytics. Using both molecular and digital tools, Guardant Health is addressing challenges across the cancer care continuum. The company has raised more than $500 million from leading investors. Its first product, the Guardant360 assay, came to market in 2014, and is now the most widely ordered comprehensive liquid biopsy commercially available. In 2016, it announced Project LUNAR, an effort to apply Guardant Health's technology platform to early detection, recurrence monitoring, and assessing minimal residual disease. Guardant Health and Guardant360 are registered trademarks of Guardant Health, Inc.
About SoftBank
SoftBank is a global technology player that aspires to drive the Information Revolution. SoftBank is comprised of the holding company SoftBank Group Corp. (TYO: 9984) and its global portfolio of companies, which includes advanced telecommunications, internet services, AI, smart robotics, IoT and clean energy technology providers. In September 2016, ARM Holdings plc, the world's leading semiconductor IP company, joined the SoftBank Group. To learn more, please visit www.softbank.jp/en
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/guardant-health-partners-with-softbank-to-accelerate-efforts-in-early-cancer-detection-300455845.html
SOURCE Guardant Health
Werbung
Mehr Nachrichten zur Softbank Group Corp. ADR Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
-1
Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink.
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
